The Age of Allo – Developing Donor-Derived Therapies with Safety and Efficacy in Mind

07 Sep 2023
Stream 3
Gift of Life Biologics


10:30am Chair Introduction

Chairperson: Jo Brewer, Chief Scientific Officer, Adaptimmune


10:35am Presentation: Designing Next-Generation Allogeneic T-cell Therapies Empowered by the Thymus

  • Producing large numbers of clinical grade T-cell progenitors through a proprietary ex vivo lymphoid niche in 7 days 
  • Harnessing the potential of T-cell progenitors to generate innovative allogeneic cellular immunotherapy products 
  • Taking advantage of the thymus to avoid graft vs. host disease in the context of allogeneic T-cell therapy

Olivier Negre, Chief Scientific Officer, Smart Immune


10:50am Presentation: International Collaboration for Starting Material to Enable Donor-Derived Cell Therapy Clinical Development 

  • Case Study of International Collaboration Sourcing Starting Material for Enable Allogeneic CGT Clinical Development 
  • Overview of Gift of Life Biologics and Cellex Offerings 
  • Accelerate CGT Development and Commercialization from Combined Offering from Gift of Life Biologics and Cellex 

Eric Strati, Chief Executive Officer, Gift of Life Biologics


11:05am Presentation: Cellectis’ Engineer’s Approaches To Safety & Efficacy: From Inventing Allo CAR T-cell To Advanced Smart Cells 

  • Transforming cell therapy by developing and leveraging the safest and most powerful gene editing approaches  
  • Transitioning cell therapy from autologous grafts to robust off-the-shelf allogeneic pharmaceutical products 
  • The next step:  unlocking the full power of cell therapies by engineering biological scenarios with the genomic design of smart cells 

David Sourdive, Co-Founder, Executive Vice President CMC & Manufacturing, Cellectis


11:20am Presentation: Molecular Shielding Protects Hematopoietic Stem Cells from Immunotherapy-Mediated Depletion

  • Cimeio’s technology platform is based on the design and expression of precision-engineered variants of cell surface receptors of the hematopoietic system 
  • We will show that such receptor variants maintain their function but are resistant to depletion by a paired immunotherapy
  • These pairs of potent immunotherapy and matching shielded cells are used to develop curative treatments for patients with genetic diseases, malignancies and autoimmune diseases 

 Stefanie Urlinger, PhD, Chief Scientific Officer, Cimeio Therapeutics


11:35pm Closing Panel with Q&A 

With all session participants and joined by:

Evren Alici, Head of Cell and Gene Therapy Group, Department of Medicine, Karolinska Institutet



Jo Brewer
Chief Scientific Officer
Olivier Negre
Chief Scientific Officer
Smart Immune
Eric Strati
Chief Executive Officer
Gift of Life Biologics
David Sourdive
Co-Founder, Executive Vice President CMC & Manufacturing
Stefanie Urlinger
Chief Scientific Officer
Cimeio Therapeutics
Evren Alici
Head of Cell and Gene Therapy Group, Department of Medicine
Karolinska Institutet